SCY-078, a Novel IV/Oral Triterpenoid Antifungal Treatment, is Not Embryo/Feto-toxic

Christina M. Carruthers, Stephen Barat, Porsha Thomas, Elise Lewis
Teratology 2018
June 2018

SCY-078: A First-in-class, Orally-bioavailable, Glucan Synthase Inhibitor has Activity Alone and is Synergistic with Azole Antifungal Agents against Aspergillus spp.

Morphological Effect of SCY-078 and Caspofungin on Different Caspofungin-Resistant Candida Species

Does Sabouraud Dextrose Broth, Compared to RPMI, Differentiate Susceptibility Between Resistant and Susceptible C. glabrata and C. albicans Isolates to SCY-078, a Novel β-D-glucan Synthase Inhibitor, and Caspofungin?

In vitro Activity of SCY-078 in Combination with Isavuconazole or Amphotericin B against Medically Important Moulds

Candida auris, A Difficult to Treat, Emerging Pathogen

S. Barat
Superbugs and Superdrugs 2018
March 2018

Combination Therapy with SCY-078 and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis

V. Petraitis, S. Barat, K. Borroto-Esoda, D. Angulo, T. Walsh
AAA 2018
February 2018

SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of Invasive Aspergillosis

K. Borroto-Esoda, S. Barat, D. Angulo, C. Carruthers, K. Holden, P. Warn
IDWeek 2017
October 2017

Assessment of the In Vitro Antifungal Activity of SCY-078 Against a Collection of C. parapsilosis Clinical Isolates

S. Barat, D. Angulo, K. Borroto-Esoda, M. Ghannoum
IDWeek 2017
October 2017

SCY-078 Demonstrates Significant Tissue Penetration in Rats and Mice Following Oral or IV Administration

S. Barat, K. Borroto-Esoda, D. Angulo, C. Carruthers
IDWeek 2017
October 2017